Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

NCT02785250 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Epithelial Ovarian Cancer
Recurrent Fallopian Tube Cancer
Recurrent Peritoneal Cancer

Interventions

OTHER: DPX-Survivac
DRUG: Cyclophosphamide
DRUG: Epacadostat (INCB024360)

Sponsor

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Collaborators

[object Object]